{'fraction_non_alphanumeric': 0.026333113890717578, 'fraction_numerical': 0.024358130348913758, 'mean_word_length': 5.909090909090909, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A new carboxamide compound exerts immuno‐suppressive activity by inhibiting dendritic cell maturation

The immunosuppressive properties of a benzamide derivative, JM34, previously characterized as an anti‐inflammatory compound are described. The immunosuppressive potential of JM34 was evidenced by inhibition of PBMC proliferation in vitro with an IC50 of 20 µM. In contrast with classical immunosuppressive drugs, JM34 affected neither cytokine production nor IL‐2R expression from activated T cell clones, and displayed only moderate inhibition of IL‐2‐induced or anti‐CD3/anti‐CD28‐induced proliferation. We investigated its effects on dendritic cells (DC) in vitro. Addition of JM34 during DC maturation inhibited the expression of some maturation markers: specifically, MHC molecule up‐regulation was totally inhibited and CD83 expression was significantly reduced, while up‐regulation of CD86, CD80 or CD40 was less affected. Moreover, JM34‐treated DC showed impaired IL‐12 but not IL‐10 secretion, and a markedly reduced ability to present antigens to naive T lymphocytes in vitro. We provide evidence that these JM34‐induced alterations of DC were associated with a marked inhibition of NF‐κB nuclear translocation. Finally, JM34 inhibited delayed type hypersensitivity dose dependently in mice. In conclusion, our data suggest that JM34 inhibited T lymphocyte activation mainly by targeting DC, and thus may represent a new class of therapeutic agents in the fields of transplantation and autoimmune diseases.